|
Neonatal Intensive Care Drug Manual
|
| bet | 380/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Naloxone
Revision Date : 16-10-2018
|
Approved : TC, KOH
|
Alert
|
Naloxone should not be administered to babies whose mothers are known or suspected to be addicted to opioids. In such cases, an abrupt and complete reversal of opioid effects may precipitate an acute withdrawal syndrome and seizures.
|
Indication
|
1. At birth – Reversal of respiratory depression secondary to maternal opioid administration.
2. Reversal of opioid effects (to facilitate extubation or avoid intubation, post-operative apnoea)
|
Action
|
Opioid antagonist. Little or no agonistic activity.
|
Drug Type
|
Semisynthetic opioid antagonist
|
Trade Name
|
DBL Naloxone Hydrochloride Injection; Naloxone Juno Solution for injection; Naloxone Min- I-jet Prefilled syringe; Narcan Solution for injection; Prenoxad Solution for injection.
|
Presentation
|
Ampoule and prefilled syringe contain 400 microgram/mL of naloxone hydrochloride. Also contains sodium chloride.
Contains 3.54 mg (0.15 mmol) of sodium. The solution is clear and colourless. pH 3.5
|
|
|
| |
